Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease
Clinical trial approval / initiationR&B Biotech

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease

GSK's Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients
GlaxoSmithKlineGSK

GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients

Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
BayerETR: BAYN

Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan

Zelgen's Jaktinib Receives NMPA Approval for Myelofibrosis Treatment
Product approvalsSHA: 688266

Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment

Show More